DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Authors :: Atish Kizhakeyil
Nurmahirah Binte Mohammed Zaini
Zhi Sheng Poh
Brandon Han Siang Wong
Xinpeng Loh
Aik Seng Ng
Zun Siong Low
Praseetha Prasannan
Chun Gong
Michelle Guet Khim Tan
Chandramouli Nagarajan
Dachuan Huang
Pang Wan Lu
Jing Quan Lim
Sharon Barrans
Choon Kiat Ong
Soon Thye Lim
Wee Joo Chng
George Follows
Daniel J. Hodson
Ming Qing Du
Yeow Tee Goh
Suat Hoon Tan
Nicholas Francis Grigoropoulos
Navin Kumar Verma
Source :: Molecular Cancer, Vol 20, Iss 1, Pp 1-7 (2021)
Publication Year :: 2021
Publisher :: BMC, 2021.

Subjects :: DDX3X mutation
Hematolymphoid malignancy
Prognosis
Tumour metastasis
Drug resistance
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools